

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF ROSSARI BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Rossari Biotech Limited ("the Company"), for the quarter and nine months ended December 31, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Deloitte Haskins & Sells LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Manoj H. Dama  
(Partner)  
(Membership No. 107723)  
(UDIN: 22107723ACCDHZ4135)

Place: Mumbai  
Date: 14<sup>th</sup> February, 2022



# ROSSARI BIOTECH LIMITED

(AN ISO9001:2005 & 14001:2015 Certified Company)

Regd. Office : 201 A & B, 2<sup>nd</sup> Floor, Akuriti Corporate Park, L.B.S. Marg, Next to GE Gardens, Kanjurmarg (W) Mumbai – 400078  
T +91-22-6123 3800 F +91-22- 25796982 E info@rossarimail.com W www.rossari.com CIN: L24100MH2009PLC194818



## STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2021

Rs. In millions

Particulars	Quarter ended			Nine months ended		Year Ended
	31st December, 2021	30th September, 2021	31st December, 2020	31st December, 2021	31st December, 2020	31st March, 2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>I INCOME</b>						
Revenue from operations	2,686.44	3,386.13	2,057.57	8,112.03	4,889.32	6,904.14
Other Income	55.98	32.76	11.04	121.49	76.69	102.09
<b>Total Income</b>	<b>2,742.42</b>	<b>3,418.89</b>	<b>2,068.61</b>	<b>8,233.52</b>	<b>4,966.01</b>	<b>7,006.23</b>
<b>II EXPENSES</b>						
Cost of materials consumed	1,830.96	1,960.28	1,471.74	5,296.87	3,200.99	4,338.78
Purchase of stock-in-trade	312.59	663.66	-	1,075.17	-	249.86
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(55.02)	52.15	(74.93)	(170.63)	(63.27)	(72.21)
Employee benefits expense	110.12	102.56	88.11	307.53	272.04	366.60
Finance costs	4.37	8.86	3.62	19.40	21.88	29.92
Depreciation and amortization expenses	67.64	63.96	58.61	191.88	151.38	220.74
Other expenses	226.81	232.73	248.56	663.66	615.19	812.56
<b>Total Expenses</b>	<b>2,497.47</b>	<b>3,084.20</b>	<b>1,795.71</b>	<b>7,383.88</b>	<b>4,198.21</b>	<b>5,946.25</b>
<b>III Profit before exceptional items and tax [I-II]</b>	<b>244.95</b>	<b>334.69</b>	<b>272.90</b>	<b>849.64</b>	<b>767.80</b>	<b>1,059.98</b>
<b>IV Exceptional items</b>	-	-	-	-	-	-
<b>V Profit before tax [III-IV]</b>	<b>244.95</b>	<b>334.69</b>	<b>272.90</b>	<b>849.64</b>	<b>767.80</b>	<b>1,059.98</b>
<b>VI Tax Expense</b>						
Current tax charge	64.08	87.08	67.53	227.67	193.47	275.30
Deferred tax charge/(credit)	(1.81)	3.52	(1.06)	(4.03)	(2.70)	(6.34)
<b>Total Tax Expense</b>	<b>62.27</b>	<b>90.60</b>	<b>66.47</b>	<b>223.64</b>	<b>190.77</b>	<b>268.96</b>
<b>VII Profit after tax [V-VI]</b>	<b>182.68</b>	<b>244.09</b>	<b>206.43</b>	<b>626.00</b>	<b>577.03</b>	<b>791.02</b>
<b>VIII Other comprehensive income / (loss)</b>						
<b>A Items that will not be reclassified to profit or loss</b>						
i Remeasurements of the defined benefit plans	0.42	0.42	(0.70)	1.26	(2.11)	1.67
ii Income tax relating to items that will not be reclassified to profit or loss	(0.11)	(0.10)	0.17	(0.32)	0.52	(0.42)
<b>B Items that will be reclassified subsequently to profit or loss</b>	-	-	-	-	-	-
<b>Total other comprehensive income/(Loss)</b>	<b>0.31</b>	<b>0.32</b>	<b>(0.53)</b>	<b>0.94</b>	<b>(1.59)</b>	<b>1.25</b>
<b>IX Total comprehensive income (VII + VIII)</b>	<b>182.99</b>	<b>244.41</b>	<b>205.90</b>	<b>626.94</b>	<b>575.44</b>	<b>792.27</b>
Paid up equity share capital (Face value of Rs. 2.00 per share)	110.11	110.11	103.86	110.11	103.86	103.86
Other equity						3,940.58
<b>X Earnings per equity share (in Rs.)</b>						
Basic	3.32*	4.44*	3.98*	11.42*	11.22*	15.34
Diluted	3.30*	4.41*	3.93*	11.35*	11.09*	15.25

\*Not annualized



**Notes:**

- 1 The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14th February, 2022.
- 2 The financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3 The Company is mainly engaged in the business of manufacturing of Specialty Chemicals for Textile, Home and Personal Care, Performance Chemicals and Animal Health and Nutrition industries. There are no reportable segments in accordance with IND AS 108 – Operating Segments.
- 4 During the quarter ended 30th September, 2021, the Company at its meeting of the Board of Directors held on 30th July, 2021 had resolved to make a strategic investment by acquiring and/or subscribing to equity shares equivalent to 50.10% of the issued and paid-up share capital of Romakk Chemicals Private Limited ("Romakk") at an aggregate consideration of Rs.75.10 million. During the current quarter, on 25th November, 2021, the Company has completed the process of the acquisition/subscription of equity shares of Romakk.
- 5 During the quarter ended 31st December, 2021, the Company has allotted 300 equity shares of Rs. 2.00/- each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan – 2019.
- 6 The Company has considered the external and internal information for assessing possible impact of COVID-19 on various elements of its financial results, including the recoverability of its assets. The Company will continue to monitor any material changes to future economic conditions and consequential impact on its financial results.



For ROSSARI BIOTECH LIMITED

A handwritten signature in blue ink, appearing to read "Edward Menezes".

**EDWARD MENEZES**  
Executive Chairman  
DIN:00149205

Place : Mumbai

Date : 14th February, 2022





## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF ROSSARI BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Rossari Biotech Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of net profit after tax and total comprehensive income of its joint venture, for the quarter and nine months ended December 31, 2021 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

- a) Rossari Biotech Limited – the Parent Company
- b) Rossari Personal Care Products Private Limited – Subsidiary
- c) Buzil Rossari Private Limited – Subsidiary (Joint Venture up to August 31, 2020; Subsidiary with effect from September 1, 2020)
- d) Unitop Chemicals Private Limited – Subsidiary (with effect from August 26, 2021)
- e) Tristar Intermediates Private Limited – Subsidiary (with effect from August 31, 2021)
- f) Hextar Unitop Sendirian Berhad- a joint venture of Unitop Chemicals Private Limited (with effect from August 26, 2021)
- g) Romakk Chemicals Private Limited- a joint venture (with effect from November 25, 2021)



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below and our reliance on the interim financial information / results certified by the Management referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information/ financial results of four subsidiaries included in the consolidated unaudited financial results, whose interim financial information/ financial results reflect total revenues of Rs 1,727.64 million and Rs. 2,702.59 million for the quarter and nine months ended December 31, 2021 respectively, total net profit after tax of Rs. 128.78 million and Rs. 226.61 million for the quarter and nine months ended December 31, 2021 respectively and total comprehensive income of Rs. 127.53 million and Rs. 224.89 million for the quarter and nine months ended December 31, 2021 respectively, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of profit after tax of Rs. 0.48 million for the quarter and nine months ended December 31, 2021 and Total comprehensive income of Rs. 0.48 million for the quarter and nine months ended December 31, 2021, as considered in the Statement, in respect of a joint venture, whose interim financial information/ financial results have not been reviewed by us. These interim financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and a joint venture, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

7. The consolidated unaudited financial results includes the Group's share of profit after tax of Rs. 1.09 million and Rs. 1.72 million for the quarter and nine months ended December 31, 2021 respectively and Group's share of total comprehensive income of Rs. 1.09 million and Rs. 1.72 million for the quarter and nine months ended December 31, 2021 respectively, as considered in the Statement, in respect of a joint venture based on their interim financial information/ financial results which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information/financial results are not material to the Group.

kd  
ml

**Deloitte  
Haskins & Sells LLP**

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information / results certified by the Management.

For **Deloitte Haskins & Sells LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



**Manoj H. Dama**  
Partner  
(Membership No. 107723)  
(UDIN: 22107723ACCFIK9744)

Place: Mumbai  
Date: 14<sup>th</sup> February, 2022





**ROSSARI BIOTECH LIMITED**  
(AN ISO9001:2005 & 14001:2015 Certified Company)



Regd. Office : 201 A & B, 2<sup>nd</sup> Floor, Akruti Corporate Park, L.B.S. Marg, Next to GE Gardens, Kanjurmarg (W) Mumbai – 400078  
T +91-22-6123 3800 F +91-22- 25796982 E info@rossarimail.com W www.rossari.com CIN: L24100MH2009PLC194818

**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2021**

Particulars	Quarter ended			Nine months ended		Rs. in Millions
	31st December, 2021	30th September, 2021	31st December, 2020	31st December, 2021	31st December, 2020	Year Ended
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>I INCOME</b>						
Revenue from operations	4,284.16	3,845.16	2,099.83	10,440.42	4,911.23	7,093.45
Other Income	63.56	39.62	7.57	133.89	63.07	91.90
<b>Total Income</b>	<b>4,347.72</b>	<b>3,884.78</b>	<b>2,107.40</b>	<b>10,574.31</b>	<b>4,974.30</b>	<b>7,185.35</b>
<b>II EXPENSES</b>						
Cost of materials consumed	2,963.20	2,255.63	1,472.10	6,721.13	3,204.45	4,348.06
Purchase of stock-in-trade	312.59	730.54	-	1,327.95	-	358.11
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(60.10)	6.87	(74.23)	(242.70)	(88.61)	(84.24)
Employee benefits expense	201.80	139.60	108.51	457.22	303.82	419.75
Finance costs	34.90	19.28	3.62	60.52	21.88	29.92
Depreciation and amortization expenses	178.19	101.90	60.65	343.28	154.43	228.29
Other expenses	399.24	273.48	252.99	899.15	613.13	821.19
<b>Total Expenses</b>	<b>4,029.82</b>	<b>3,527.30</b>	<b>1,823.64</b>	<b>9,566.55</b>	<b>4,209.10</b>	<b>6,121.08</b>
<b>III Profit before Share of profit of joint ventures, exceptional items and tax [I-II]</b>	<b>317.90</b>	<b>357.48</b>	<b>283.76</b>	<b>1,007.76</b>	<b>765.20</b>	<b>1,064.27</b>
<b>IV Share of profit of joint ventures</b>	<b>1.57</b>	<b>0.63</b>	<b>-</b>	<b>2.20</b>	<b>4.11</b>	<b>4.11</b>
<b>V Profit before exceptional items and tax [III+IV]</b>	<b>319.47</b>	<b>358.11</b>	<b>283.76</b>	<b>1,009.96</b>	<b>769.31</b>	<b>1,068.38</b>
<b>VI Exceptional items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>VII Profit before tax [V-VI]</b>	<b>319.47</b>	<b>358.11</b>	<b>283.76</b>	<b>1,009.96</b>	<b>769.31</b>	<b>1,068.38</b>
<b>VIII Tax Expense</b>						
Current tax charge	151.54	102.41	67.53	346.44	193.47	276.98
Deferred tax charge/(credit)	(57.46)	(6.59)	0.04	(69.59)	(2.57)	(9.06)
<b>Total Tax Expense</b>	<b>94.08</b>	<b>95.82</b>	<b>67.57</b>	<b>276.85</b>	<b>190.90</b>	<b>267.92</b>
<b>IX Profit after tax [VII-VIII]</b>	<b>225.39</b>	<b>262.29</b>	<b>216.19</b>	<b>733.11</b>	<b>578.41</b>	<b>800.46</b>
<b>X Other comprehensive income / (loss)</b>						
<b>A Items that will not be reclassified to profit or loss</b>						
i Remeasurements of the defined benefit plans	(1.62)	(0.10)	(0.70)	(1.30)	(2.11)	1.52
ii Income tax relating to items that will not be reclassified to profit or loss	0.68	0.03	0.17	0.60	0.52	(0.46)
<b>B Items that will be reclassified subsequently to profit or loss</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total other comprehensive income/(Loss)</b>	<b>(0.94)</b>	<b>(0.07)</b>	<b>(0.53)</b>	<b>(0.70)</b>	<b>(1.59)</b>	<b>1.06</b>
<b>XI Total comprehensive income (IX + X)</b>	<b>224.45</b>	<b>262.22</b>	<b>215.66</b>	<b>732.41</b>	<b>576.82</b>	<b>801.52</b>
<b>Profit / Loss for the year attributable to</b>						
Owners of the Company	225.39	262.29	216.01	732.90	577.93	802.20
Non Controlling Interest	-	-	0.18	0.21	0.48	(1.74)
	<b>225.39</b>	<b>262.29</b>	<b>216.19</b>	<b>733.11</b>	<b>578.41</b>	<b>800.46</b>
<b>Other Comprehensive Income/(Loss) for the year attributable to</b>						
Owners of the Company	(0.94)	(0.07)	(0.53)	(0.70)	(1.59)	1.06
Non Controlling Interest	-	-	-	-	-	-
	<b>(0.94)</b>	<b>(0.07)</b>	<b>(0.53)</b>	<b>(0.70)</b>	<b>(1.59)</b>	<b>1.06</b>
<b>Total Comprehensive Income / (loss) for the year attributable to</b>						
Owners of the Company	224.45	262.22	215.48	732.20	576.34	803.26
Non Controlling Interest	-	-	0.18	0.21	0.48	(1.74)
	<b>224.45</b>	<b>262.22</b>	<b>215.66</b>	<b>732.41</b>	<b>576.82</b>	<b>801.52</b>
<b>Paid up equity share capital (Face value of Rs 2.00 per share)</b>	<b>110.11</b>	<b>110.11</b>	<b>103.86</b>	<b>110.11</b>	<b>103.86</b>	<b>103.86</b>
<b>Other equity</b>						<b>3,983.86</b>
<b>Earnings per equity share (in Rs.)</b>						
Basic	4.09*	4.77*	4.16*	13.37*	11.24*	15.56
Diluted	4.07*	4.74*	4.11*	13.29*	11.12*	15.47

\*Not annualized



M

**Notes:**

- 1 The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14th February, 2022.
- 2 The financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3 The Group is mainly engaged in the business of manufacturing of Specialty Chemicals for Textile, Home and Personal Care, Performance Chemicals and Animal Health and Nutrition industries. There are no reportable segments in accordance with IND AS 108 – Operating Segments.
- 4 a On 26th August, 2021, Rossari Biotech Limited ("Parent Company") has completed the acquisition of 65% equity shares of Unitop Chemicals Private Limited (UCPL) for an aggregate consideration of Rs. 2,697.46 million from the existing shareholders. Further the balance 35% equity shares will be acquired in multiple tranches, subject to completion of the customary terms and conditions.  
  
As per IND AS 103, purchase consideration has been allocated on a provisional basis, pending the final determination of the fair value of assets and liabilities.
- b On 30th August, 2021, the Parent Company has completed the acquisition of 76% equity shares of Tristar Intermediates Private Limited (TIPL) for an aggregate consideration of Rs. 821.41 million from the existing shareholders. Further the balance 24% equity shares will be acquired in multiple tranches, subject to completion of the customary terms and conditions.  
  
As per IND AS 103, purchase consideration has been allocated on a provisional basis, pending the final determination of the fair value of assets and liabilities.  
  
Results for the quarter and nine months ended 31st December, 2021 includes results of UCPL and TIPL from the date of acquisition till 31st December, 2021 and hence the results for current quarter and nine months ended 31st December, 2021 are not comparable with the previous periods.
- 5 The Parent Company at the meeting of its Board of Directors held on 30th July, 2021 has resolved to make a strategic investment by acquiring and/or subscribing to equity shares equivalent to 50.10% of the issued and paid-up share capital of Romakk Chemicals Private Limited ("Romakk") at an aggregate consideration of Rs. 75.10 million. During the current quarter on 25th November, 2021, the Company has completed the process of the acquisition/subscription of equity shares of Romakk.
- 6 During the quarter ended 31st December, 2021, the Parent company has allotted 300 equity shares of Rs. 2.00/- each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan – 2019.
- 7 The Group has considered the external and internal information for assessing possible impact of COVID-19 on various elements of its financial results, including the recoverability of its assets. The Group will continue to monitor any material changes to future economic conditions and consequential impact on its financial results.

**For ROSSARI BIOTECH LIMITED****EDWARD MENEZES**  
**Executive Chairman**  
DIN:00149205

Place : Mumbai

Date : 14th February, 2022

